NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.60.

NPCE has been the topic of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday, August 14th. Wells Fargo & Company reduced their price target on NeuroPace from $15.00 to $13.00 and set an "overweight" rating for the company in a research report on Wednesday, November 13th.

Insider Transactions at NeuroPace

In other news, major shareholder Ltd. Kck sold 4,031 shares of NeuroPace stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $6.54, for a total transaction of $26,362.74. Following the sale, the insider now owns 5,521,874 shares in the company, valued at $36,113,055.96. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 257,590 shares of company stock valued at $1,437,916 over the last 90 days. Company insiders own 22.20% of the company's stock.

Hedge Funds Weigh In On NeuroPace

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company's stock worth $6,450,000 after acquiring an additional 75,512 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of NeuroPace in the 2nd quarter valued at about $257,000. Financial Advocates Investment Management increased its position in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company's stock valued at $113,000 after purchasing an additional 5,000 shares during the last quarter. Rhumbline Advisers purchased a new stake in NeuroPace during the 2nd quarter valued at $111,000. Finally, Acadian Asset Management LLC boosted its stake in NeuroPace by 46.0% during the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company's stock worth $520,000 after buying an additional 21,703 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Stock Performance

NPCE stock traded up $0.96 on Monday, hitting $10.66. The company had a trading volume of 169,118 shares, compared to its average volume of 97,543. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.15. The stock has a market cap of $318.20 million, a price-to-earnings ratio of -10.66 and a beta of 1.79. The stock's 50-day simple moving average is $7.20 and its 200 day simple moving average is $7.26.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The firm had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. During the same period last year, the business posted ($0.28) EPS. As a group, equities research analysts expect that NeuroPace will post -1 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.